Related references
Note: Only part of the references are listed.Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras
Michael J. Cavnar et al.
ANNALS OF SURGERY (2021)
PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia
Yu-Chen Enya Chen et al.
LEUKEMIA (2020)
A comparative study of small molecules targeting eIF4A
Sai Kiran Naineni et al.
RNA (2020)
MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib
Wei Chen et al.
CELL DEATH & DISEASE (2020)
PI3K/AKT/mTOR pathway and autophagy regulator genes in paranasal squamous cell carcinoma metastasis
Cigir Biray Avci et al.
MOLECULAR BIOLOGY REPORTS (2020)
Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy
Zhenru Xu et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2020)
Secondary KIT mutations: the GIST of drug resistance and sensitivity
Andrea Napolitano et al.
BRITISH JOURNAL OF CANCER (2019)
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Cesar Serrano et al.
BRITISH JOURNAL OF CANCER (2019)
Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1 in cancer
Yoshihiro Hayashi et al.
CANCER SCIENCE (2019)
Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels
Rita Seeboeck et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
PI3K pathway defects leading to immunodeficiency and immune dysregulation
Cristiane J. Nunes-Santos et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
Meran Keshawa Ediriweera et al.
SEMINARS IN CANCER BIOLOGY (2019)
Revisiting mTOR inhibitors as anticancer agents
Qiu-Xu Teng et al.
DRUG DISCOVERY TODAY (2019)
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Ali S. Alzahrani
SEMINARS IN CANCER BIOLOGY (2019)
Association between CT imaging features and KIT mutations in small intestinal gastrointestinal stromal tumors
Yi-qiong Yin et al.
SCIENTIFIC REPORTS (2019)
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
Alia Ghoneum et al.
CANCERS (2019)
Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy
Jean Christopher Chamcheu et al.
CELLS (2019)
EIF3B is associated with poor outcomes in gastric cancer patients and promotes cancer progression via the PI3K/AKT/mTOR signaling pathway
Lin Wang et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors
Yuzhi Pang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Translational control in brain pathologies: biological significance and therapeutic opportunities
Alberto Delaidelli et al.
ACTA NEUROPATHOLOGICA (2019)
Metformin Induces Apoptosis and Inhibits Proliferation through the AMP-Activated Protein Kinase and Insulin-like Growth Factor 1 Receptor Pathways in the Bile Duct Cancer Cells
Jin Lee et al.
JOURNAL OF CANCER (2019)
Classification of gastrointestinal stromal tumor syndromes
Priya Gopie et al.
ENDOCRINE-RELATED CANCER (2018)
Clinicopathological and Molecular Factors, Risk Factors, Treatment Outcomes and Risk of Recurrence in Mesenteric and Retroperitoneal Extragastrointestinal Stromal Tumors
Konstantinos G. Apostolou et al.
ANTICANCER RESEARCH (2018)
Systematic review of current prognostication systems for primary gastrointestinal stromal tumors
Chun Yuet Khoo et al.
EJSO (2018)
Gastrointestinal Stromal Tumors
Margaret von Mehren et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis
Seong-Jang Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome
Nikolaos Settas et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1
Tianyu Han et al.
AUTOPHAGY (2018)
Clinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients
Ming-Lei Yang et al.
ONCOLOGY LETTERS (2018)
New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors
Nicole Golob-Schwarzl et al.
EUROPEAN JOURNAL OF CANCER (2017)
Emerging drugs for the treatment of gastrointestinal stromal tumour
Vineela Kasireddy et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications
Zoltan Szucs et al.
FUTURE ONCOLOGY (2017)
Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer
Rehman Ata et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels
Paolo G. Casali et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment A meta-analysis
Zhenan Zhang et al.
MEDICINE (2017)
mTOR-sensitive translation: Cleared fog reveals more trees
Laia Masvidal et al.
RNA BIOLOGY (2017)
Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6
Nicole Golob-Schwarzl et al.
ONCOTARGET (2017)
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
Wennan Zhao et al.
ACTA PHARMACEUTICA SINICA B (2017)
Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies.
D. Mahadevan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib
Chien-Feng Li et al.
CLINICAL CANCER RESEARCH (2017)
Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor
Jian Li et al.
CHINESE JOURNAL OF CANCER RESEARCH (2017)
Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review
Antonia Dimitrakopoulou-Strauss et al.
CLINICAL AND TRANSLATIONAL IMAGING (2017)
Carney triad can be (rarely) associated with germline succinate dehydrogenase defects
Sosipatros A. Boikos et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2016)
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
Kjetil Soreide et al.
CANCER EPIDEMIOLOGY (2016)
Molecular Genetics of the PI3K-AKT-mTOR Pathway in Genodermatoses: Diagnostic Implications and Treatment Opportunities
Hassan Vahidnezhad et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants
Ke Chen et al.
ONCOTARGET (2016)
Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature
Nasir Ud Din et al.
Asian Pacific Journal of Cancer Prevention (2015)
PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma
Mirela S. Petrulea et al.
CANCER TREATMENT REVIEWS (2015)
KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence
Heikki Joensuu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs)
Jian Li et al.
MEDICAL ONCOLOGY (2015)
miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours
Michaela Angelika Ihle et al.
MOLECULAR ONCOLOGY (2015)
Gastrointestinal Stromal Tumor: Optimizing the Use of Cross-sectional Chest Imaging during Follow-up
Atul B. Shinagare et al.
RADIOLOGY (2015)
Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis
Lin Yan et al.
SCIENTIFIC REPORTS (2015)
Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Thomas Van Looy et al.
CLINICAL CANCER RESEARCH (2014)
Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors
Anna Quattrone et al.
MODERN PATHOLOGY (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance
Oscar Tapia et al.
VIRCHOWS ARCHIV (2014)
Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition
Ying-Yu Ma et al.
ONCOTARGETS AND THERAPY (2014)
Gastrointestinal stromal tumors (GIST) related emergencies
Magdy A. Sorour et al.
INTERNATIONAL JOURNAL OF SURGERY (2014)
MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
Yuan-Shuo Hsueh et al.
ONCOTARGET (2014)
Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors
Yuan-Shuo Hsueh et al.
AUTOPHAGY (2013)
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Giuseppe Floris et al.
CLINICAL CANCER RESEARCH (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Practical Role of Mutation Analysis for Imatinib Treatment in Patients With Advanced Gastrointestinal Stromal Tumors: A Meta-Analysis
Xiaofei Zhi et al.
PLOS ONE (2013)
Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway
Shreyaskumar Patel
CURRENT ONCOLOGY REPORTS (2013)
Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A
R. Cencic et al.
BLOOD CANCER JOURNAL (2013)
Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience
A. Wozniak et al.
ANNALS OF ONCOLOGY (2012)
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Philippe A. Cassier et al.
CLINICAL CANCER RESEARCH (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
PI3K signalling: the path to discovery and understanding
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group
Janine Kalkmann et al.
CANCER IMAGING (2012)
Principles of Translational Control: An Overview
John W. B. Hershey et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
The Activated Targets of mTOR Signaling Pathway Are Characteristic for PDGFRA Mutant and Wild-type Rather Than KIT Mutant GISTs
Zoltan Sapi et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2011)
Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor
J. Li et al.
EJSO (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
A. J. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Status of PI3K inhibition and biomarker development in cancer therapeutics
B. Markman et al.
ANNALS OF ONCOLOGY (2010)
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
P. Schoffski et al.
ANNALS OF ONCOLOGY (2010)
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours
Marco Novelli et al.
HISTOPATHOLOGY (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
Maria Abbondanza Pantaleo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
The mechanism of eukaryotic translation initiation and principles of its regulation
Richard J. Jackson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)
Anu Gupta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Ben Markman et al.
ONCOTARGET (2010)
Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract
Pedro J. Gomez-Pinilla et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors A Study of 1840 Cases
Markku Miettinen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors
Severine Tabone-Eglinger et al.
CLINICAL CANCER RESEARCH (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine
Debraj Shome et al.
OPHTHALMOLOGY (2008)
Is Autophagy Rather Than Apoptosis the Regression Driver in Imatinib-Treated Gastrointestinal Stromal Tumors?
Francesca Miselli et al.
TRANSLATIONAL ONCOLOGY (2008)
Pulmonary chondroma: A tumor associated with Carney triad and different from pulmonary hamartoma
Fausto J. Rodrigue et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
S. Bauer et al.
ONCOGENE (2007)
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase-mediated mTOR activation in tuberous sclerosis and human cancer
Li Ma et al.
CANCER RESEARCH (2007)
Study of the expressions of p53 and bcl-2 genes, the telomerase activity and apoptosis in GIST patients
Qiang Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors
Brian S. Chang et al.
MODERN PATHOLOGY (2007)
ATG1, an autophagy regulator, inhibits cell growth by negatively regulating S6 kinase
Sung Bae Lee et al.
EMBO REPORTS (2007)
Direct induction of autophagy by Atg1 inhibits cell growth and induces apoptotic cell death
Ryan C. Scott et al.
CURRENT BIOLOGY (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Gastrointestinal stromal tumours:: a regular origin in the muscularis propria, but an extremely diverse gross presentation -: A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours
Abbas Agaimy et al.
LANGENBECKS ARCHIVES OF SURGERY (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Initial and late resistance to imatinib in advanced gastrointestinal stromal. tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study
M Van Glabbeke et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
GI hemorrhage with fulminant shock induced by jejunal gastrointestinal stromal tumor (GIST) coincident with duodenal neuroendocrine carcinoma (NET) plus neurofibromatosis (NF) -: Case report and review of the literature
K Kramer et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2005)
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors
BA Ballif et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The role of autophagy in cancer development and response to therapy
Y Kondo et al.
NATURE REVIEWS CANCER (2005)
Gastrointestinal stromal tumors of the stomach - A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up
M Miettinen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
c-Kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue)
H Yamamoto et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
PI3K/Akt signalling pathway and cancer
JAF Vara et al.
CANCER TREATMENT REVIEWS (2004)
PDK1, the master regulator of AGC kinase signal transduction
A Mora et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2004)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
HG Wendel et al.
NATURE (2004)
A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential
J Lasota et al.
LABORATORY INVESTIGATION (2004)
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
DC Fingar et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
PI3K-Akt pathway: Its functions and alterations in human cancer
M Osaki et al.
APOPTOSIS (2004)
Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors
E Wardelmann et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
JB Brugarolas et al.
CANCER CELL (2003)
Malignant gastrointestinal stromal tumor: Distribution, imaging features, and pattern of metastatic spread
GJC Burkill et al.
RADIOLOGY (2003)
Tor-mediated induction of autophagy via an Apg1 protein kinase complex
Y Kamada et al.
JOURNAL OF CELL BIOLOGY (2000)
Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival
RP DeMatteo et al.
ANNALS OF SURGERY (2000)
Share Paper
